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A B S T R A C T
Purpose: Vagus nerve stimulation (VNS) therapy is a procedure to control seizure frequency in patients
with medically intractable epilepsy. However, there is no data on efﬁcacy in the subset of these patients
with brain tumors. The purpose of this study is to evaluate the efﬁcacy of VNS therapy in patients with
brain tumor-associated medically intractable epilepsy.
Methods: Data from the VNS therapy Patient Outcome Registry, maintained by the manufacturer of the
device, Cyberonics Inc. (Houston, TX, USA), was queried to characterize the response of patients in whom
a brain tumor was listed as the etiology of epilepsy. A case–control analysis was implemented and
patient outcome was measured by Engel classiﬁcation, median seizure response and responder rate
(50% seizure reduction) using t-tests and chi-squared tests.
Results: In 107 patients with an epilepsy etiology related to a brain tumor, seizure reduction was 45% at 3
months and 79% at 24 months with a responder rate of 48% at 3 months and 79% at 24 months. There was
no statistical difference in seizure reduction compared with 326 case–control patients from the registry
without brain tumors. There was no signiﬁcant difference in anti-epileptic drug (AED) usage from
baseline to 24 months post implant in either group.
Conclusions: VNS therapy is equally effective in patients who suffer seizures secondary to brain tumors
as in patients without history of a brain tumor. VNS therapy is a viable treatment option for patients with
brain tumor associated medically intractable epilepsy, assuming cytoreductive and other adjuvant
therapies have been fully explored.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Approximately 25% of epilepsy patients remain refractory to
antiepileptic drugs (AEDs).1,2 An alternative treatment option is
vagal nerve stimulation (VNS).3 VNS therapy (Cyberonics Inc.,
Houston, TX, USA) is used as an adjunctive therapy in reducing the
frequency of partial onset seizures in medically refractory
patients.4
Numerous studies have supported VNS therapy for medically
intractable epilepsy.5–9 However, patient characteristics predictive* Corresponding author at: Department of Neurological Surgery, Weill Cornell
Medical College, New York Presbyterian Hospital, 525 East 68th Street, Box #99,
New York, NY 10065, USA. Tel.: +1 212 746 5620; fax: +1 212 746 8947.
E-mail address: schwarh@med.cornell.edu (T.H. Schwartz).
URL: http://www.cornellneurosurgery.com
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.04.017of responsiveness to VNS therapy remain unknown. Studies have
yet to consistently ﬁnd association between VNS therapy
responsiveness and patient features.10,11
VNS therapy has not been prospectively studied in patients
with partial seizures caused by the presence of a brain tumor.
Approximately 30–50% of brain tumor patients will have a seizure
at some point12 and approximately 30% of these will become
intractable.13 The treatment of choice for these tumors is surgical
resection, a procedure capable of achieving seizure freedom in 30–
60% of cases.14–17 However, there exists a subset of tumor patients
in whom removal of the tumor does not control seizures either due
to incomplete tumor resection or establishment of an independent
seizure focus.12,18,19 Only a portion of these patients may be
candidates for epilepsy surgery.19,20 In this group, seizure control
can be extremely important for the quality of life.21–23
There are no reports establishing the efﬁcacy of VNS for tumor-
related epilepsy and hence little data to serve physicians. The aimvier Ltd. All rights reserved.
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control in patients with brain tumor-associated intractable
epilepsy.
2. Methods
The study leveraged data from the VNS therapy Patient
Outcome Registry maintained by the manufacturer of the device,
Cyberonics Inc. Data were prospectively and voluntarily provided
by 1285 prescribing physicians from 978 centers (911 in the U.S.
and Canada and 67 international) at patients’ pre-operative
baselines and intervals post-VNS implantation. Neurologists sent
case report forms (CRFs) based on patient medical history to
Cyberonics. At baseline, a patient history and implant form was
submitted to collect information on patient demographics,
epilepsy etiology and syndrome, medical history, baseline seizure
types and monthly frequencies, current AEDs, and quality of life
assessments. At each follow-up visit of 3, 6, 12, and 24 months
post-implantation, information was collected on seizure types,
seizure frequency (overall and by seizure type), current AEDs, and
quality of life assessments. An independent auditing agency has
previously authenticated the integrity of the systems for collecting
and processing the registry data.24 Active data collection ceased in
2003, and the registry was queried in March 2012 to characterize
the response of patients with intractable epilepsy associated with a
history of brain tumors.
Patients with brain tumors were initially identiﬁed from the
CRFs as having any history of a brain tumor. The listed epilepsy
etiologies and brain tumor information for these patients were
reviewed, and only patients with an etiology related to the brain
tumor remained in the study (e.g. ‘‘brain tumor’’, ‘‘astrocytoma’’,
‘‘meningioma’’, ‘‘oligodendroglioma’’, etc.) while patients with
possibly unrelated epilepsy etiologies were removed (e.g. ‘‘tuber-
ous sclerosis’’, ‘‘no information’’, ‘‘hamartoma’’, ‘‘brain injury’’,
etc.). Follow-up visits of 3, 6, 12 and 24 months were examined,
and the response of each VNS therapy patient was calculated as the
percent decrease of overall seizure frequency by comparing the
seizure frequency reported by the treating neurologist at each
follow-up visit (via a 1 month average) to the pre-operative
baseline recording (via a 3 month average). The patients were
classiﬁed according to the Engel classiﬁcation scheme.25 Patients
were designated as a ‘‘responder’’ if they had at least a 50%
reduction in seizures from their baseline frequency.
It was desired to compare these results against VNS therapy
patients without brain tumor history as the efﬁcacy of VNS therapy
for all patients with partial onset seizures is well established.4,5 A
case–control study design was utilized that matched two non-
brain tumor patients for each brain tumor patient at each available
follow-up visit. Patients were excluded from the study if they had
no speciﬁed etiology or if there were no data for any follow-up
visits. A sub-analysis of brain tumor patients who had undergone
resection surgery prior to receiving VNS was also performed with
seizure response outcomes reported only at 12 months due to
small sample size.
Two controls without brain tumors from the same VNS therapy
Patient Outcome Registry were selected for each case with brain
tumors, without any consideration of the response variables based
on the following criteria to control potentially confounding
variables: match of follow-up period, match of gender, age of
implant within 8 years, age of diagnosis within 8 years, and
baseline seizure frequency within 60%. For the 9% of brain tumor
patients with a missing age of diagnosis, the two controls were
selected without restriction on age of diagnosis, but the age of
implant was still included; no other variables had any missing
data. If at least two non-brain tumor controls met all of the above
criteria, the two that most closely matched the seizure type proﬁleof the case were selected, with exact matches made where
possible. If two appropriate controls were not found, then the brain
tumor case was not included. This methodology allowed for close
matches at each follow-up visit period where the outcome analysis
was to be performed, and the case–control selection was
considered acceptable if all potential confounders had a non-
signiﬁcant two-sided p-value > 0.05 for unique patients included
in the study. Patient gender, race, age at diagnosis, age at
implantation, pre-operative duration of epilepsy, baseline seizure
frequency, baseline seizure type, and number of AEDs were
compared for patients with brain tumors versus patients without
non-brain tumors. Student’s t-tests were used to compare means
of continuous variables, unless the data were non-normal (i.e.
baseline seizure frequency), in which case the Wilcoxon Rank-Sum
test was used to compare medians; chi-squared tests were used for
categorical variables.
Patient outcome was measured by Engel classiﬁcation,
median seizure response and responder rate (i.e. percentage
of patients with at least 50% seizure reduction from baseline).
The Cochran–Mantel–Haenszel statistic for row means scores
was used to test whether there was a relationship between brain
tumor status and Engel class, controlling for the four follow-up
time points in all instances. An odds ratio with 95% conﬁdence
interval (CI) was calculated to measure the overall likelihood of
achieving clinical response (50% reduction in seizure frequen-
cy) between patients with and without brain tumors, utilizing
the Breslow–Day test for homogeneity of the odds ratios at the
different follow-up times. 95% CIs were calculated for median
seizure response using distribution-free limits and for responder
rate using score conﬁdence limits. The Wilcoxon Rank-Sum test
and two-proportion z-test were used to compare median
percent decrease in seizure frequency and responder rates,
respectively, between patients with and without brain tumors at
each follow-up visit. Power analysis was performed at 12 and 24
months to detect a 20% difference in responder rates. All
statistical analyses were performed using SAS 9.2 (SAS Institute
Inc., Cary, NC).
3. Results
The response rates of VNS therapy patients with an epilepsy
etiology related to their brain tumor history and VNS therapy
patients without a history of any brain tumor were calculated from
7383 total individuals in the VNS therapy Patient Outcome
Registry. Individuals without a speciﬁed etiology or brain tumor
history were excluded from the study, as well as those without any
data on follow-up visits (Fig. 1A). In total, the registry contained
244 follow-up visits for 114 brain tumor patients and 3846 follow-
up visits for 1780 non-brain tumor patients.
Initial analysis of the overall groups showed similarly improv-
ing response rates over time for both groups (Fig. 2). The median
seizure reduction in brain tumor patients increased from 49% (CI:
33%, 58%) at 3 months to 82% (CI: 68%, 94%) at 24 months,
marginally better than the results of non-brain tumor patients of
44% (CI: 40%, 50%) at 3 months and 61% (CI: 54%, 67%) at 24 months.
Likewise, the clinical response rate of brain tumor patients
increased from 49% (CI: 40%, 59%) at 3 months to 78% (CI: 58%,
90%) at 24 months, with a similar increase in non-brain tumor
patients of 48% (CI: 46%, 51%) at 3 months to 61% (CI: 56%, 65%) at
24 months. However, comparing potential confounders showed
signiﬁcant differences between the two overall groups in age of
implant, age of diagnosis, and baseline seizure types (Table 1A and
Fig. 4A). Therefore the raw responses could not be directly
compared between the two groups. As a result, a case–control
study was utilized to match each available follow-up visit for
all brain tumor patients with two similar follow-up visits from
Fig. 1. Study design summary. Data pertaining to patients with and without brain tumor history were extracted from 7383 total individuals in the VNS therapy Patient
Outcome Registry (A). Individuals without a speciﬁed etiology or brain tumor history were excluded from the study, as well as those without any data on follow-up visits.
Solid lines indicate included patients; dashed lines indicate excluded patients. Of the 114 brain tumor patients with a known epilepsy etiology related to the tumor, 107
patients had at least one follow-up visit matched to two non-brain tumor patient follow-up visits (B).
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Fig. 2. Raw data depicting seizure outcomes after VNS therapy in brain tumor patients (BTP) versus non-BTP. Median percent decrease in seizure frequency (A) and responder
rates (B) are shown for BTP and non-BTP patients after VNS therapy at 3, 6, 12, and 24 months. Engel outcomes are shown at 3 months (C) and 24 months (D) after VNS therapy.
For (A–D), statistical analysis is deferred given unequal samples (see Table 1). N = 93, 73, 55, and 12 for BTP and 1509, 1004, 943, and 390 for non-BTP at 3, 6, 12, and 24
months, respectively.
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Fig. 3. Case–control design data depicting seizure outcomes after VNS therapy in BTP versus non-BTP. Median percent decrease in seizure frequency (A) and responder rates
(B) are shown for BTP and non-BTP patients after VNS therapy at 3, 6, 12, and 24 months. Engel outcomes are shown at 3 months (C) and 24 months (D) after VNS therapy.
Statistical signiﬁcance (P < 0.05) was not reached at any time point between BTP and non-BTP for any seizure outcome measure. For A and B, statistical analysis reﬂects
Wilcoxon Rank-Sum test and two-proportion z-test, respectively. For (C and D), statistical analysis reﬂects Cochran–Mantel–Haenszel statistic for row means scores. N = 86,
70, 52, and 19 for BTP and 172, 140, 104, and 38 for non-BTP at 3, 6, 12, and 24 months, respectively.
K.S. Patel et al. / Seizure 22 (2013) 627–633630non-brain tumor patients matched for age of implant, age of
diagnosis, and baseline seizure rate. There was no matching for the
response variables. Additional variables (i.e. gender, race, and
baseline seizure frequency) that were not signiﬁcantly differentTable 1
Demographics of BTP versus non-BTP.
Variable BTP patients (% or mean  SD) 
A. Raw patient data
Gender 51% male 
49% female 
Race 83% White; 3% Black; 7% Hispanic; 7% o
Age of implant 34.4  13.8 years 
Age of diagnosis 14.2  14.8 years 
Pre-operative duration of epilepsy 20.2  12.8 years 
Baseline seizure frequencya 25.0  16.0 per month 
Baseline AEDs 2.28  0.81 
B. Case–control data
Gender 51% male 
49% male 
Race 83% White; 2% Black; 8% Hispanic; 7% o
Age of implant 33.2  13.2 years 
Age of diagnosis 12.8  13.6 years 
Pre-operative duration of epilepsy 20.4  12.4 years 
Baseline seizure frequencya 20.0  15.0 per month 
Baseline AEDs 2.27  0.79 
For A: N = 114 brain tumor patients (BTP) and 1780 non-brain tumor patients (non-BT
a For baseline seizure frequency, median and MAD (median absolute deviation) are 
* P-value reﬂects Student’s t-test to compare the means of continuous variables, unle
compare medians (i.e. baseline seizure frequency); chi-squared test were used for cate
** Statistically signiﬁcant value (P < 0.05).between the two groups were included in the matching control
process as they are potentially relevant covariates or relate directly
to the response calculations. A total of 17 follow up visits for
patients with brain tumors were excluded from the study due toNon-BTP patients (% or mean  SD) P-value*
55% male 0.38
45% male
ther 83% White; 5% Black; 7% Hispanic; 5% other 0.58
26.9  15.5 years <0.001**
7.1  10.0 years <0.001**
19.8  13.5 years 0.79
28.0  24.0 per month 0.06
2.49  0.90 0.01**
51% male 0.93
49% male
ther 83% White; 5% Black; 6% Hispanic; 6% other 0.50
32.2  12.7 years 0.52
10.2  11.5 years 0.06
22.2  12.2 years 0.21
15.9  12.1 per month 0.27
2.35  0.86 0.37
P). For B: N = 107 (BTP) and 326 (non-BTP).
reported instead of mean and standard deviation.
ss data were non-normal, in which case the Wilcoxon Rank-Sum test was used to
gorical variables.
A 
 
3month  SPS  GT C Absence  Other   CPS Se cond-GT C Drop  Aack  Aura  
BTP 25 11   2  4 70  17   5  6 
non-BTP 265  464  181  220 1171  550  197  89  
P-Val ue <.01   <.01   0.01  0.02 0.06  0.01  0.08  0.53  
 
B 
 
24 month  SPS  GT C Absence  Other   CPS Se cond-GT C Drop  Aack  Aura  
BTP 23 15   2  5 81  18   7  8 
non-BTP 52 50  17  22  255  70  17  21  
P-Val ue 0.19  0.74  0.14  0.44 0.58  0.3 0 0.6 0 0.71  
 
SPS GT C Absence Ot her CPS Second-GTC
Drop 
Aa ck Aura
BTP 27% 12 % 2% 4% 75 % 18 % 5% 6%
non-BTP 15% 26 % 10 % 12 % 66 % 31 % 11 % 5%
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BTP 21% 14 % 2% 5% 76 % 17 % 7% 7%
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Fig. 4. Baseline seizure types. Baseline seizure types are shown for BTP versus non-BTP using raw data (A) and following case–control selections (B). Many patients presented
with multiple seizure types, so each seizure type was analyzed separately using chi-square tests to show that no difference existed between the groups after matching.
*Statistically signiﬁcant value (P < 0.05). CPS, complex partial seizure; GTC, generalized tonic-clonic seizure; second-GTC, secondarily generalized tonic-clonic seizure; SPS,
simple partial seizure.
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brain tumors; the excluded visits numbered 7, 3, 3 and 4 at months
3, 6, 12 and 24, respectively. The remaining 227 follow-up patient
visits for 107 brain tumor patients and 454 follow-up visits for 326
non-brain tumor patients were used for the remainder of the
analysis (Fig. 1B). After case–control selection, the baselinedemographics of all identiﬁed potential confounders were no
longer signiﬁcantly different, indicating a successful control
selection (Table 1B). As many patients presented with multiple
seizure types, each seizure type was analyzed separately to show
that no difference existed between the groups after matching
(Fig. 4B).
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selection, and analysis shows that the difference in the group
means was not signiﬁcant after the matching was performed
(P = 0.37) (Table 1). The average number of AEDs that the patients
was taking also were not signiﬁcantly different between the groups
at 24 months after VNS therapy (P = 0.65). For patients in both
groups followed at least two years, the change in average number
of AEDs from baseline to the 24 month follow-up visit was
insigniﬁcant (from 2.00 to 1.79 for brain tumor patients, P = 0.46,
and from 2.05 to 1.92 for non-brain tumor patients, P = 0.54).
Once the case–control study design was applied, the two
groups’ seizure responses were similar to the raw analysis, prior to
the case–control design, with improvement over time but no
signiﬁcant differences between the two groups in any response
measure at any of the four time points (Fig. 3). The median seizure
reduction in brain tumor patients increased from 45% (CI: 33%,
53%) at 3 months to 79% (CI: 68%, 94%) at 24 months (both
statistically different from no improvement, P < 0.001), but the
results were not statistically different from non-brain tumor
patients at the same post-operative follow-up time points (P = 0.45
and P = 0.21, respectively). Likewise, the rate of clinical response of
brain tumor patients increased from 48% (CI: 37%, 58%) at 3 months
to 79% (CI: 57%, 91%) at 24 months without a signiﬁcant difference
when compared to non-brain tumor patients (P = 0.79 and P = 0.31,
respectively). The odds ratio for brain tumor patients to have a
clinical response to VNS therapy versus their non-brain tumor
counterparts was 0.97 with a non-signiﬁcant conﬁdence interval of
0.70–1.34. The Breslow–Day Test (P = 0.75) indicated that the odds
ratio is the same across the four follow-up visits.
Furthermore, there is no association between the patient’s brain
tumor status and Engel classiﬁcation response when controlling
for the four follow-up durations (P = 0.86, Cochran–Mantel–
Haenszel statistic).
With 52 brain tumor patients at 12 months the power was 66%
for detecting a 20% difference in responder rate, and with 19 brain
tumor patients at 24 months the power for detecting the same
difference was 27%.
The sub-analysis of brain tumor patients who underwent
resection surgery, as reported in the registry, prior to receiving VNS
Therapy included 23 of the 52 matched brain tumor patients at 12
months, and this subset experienced a median seizure reduction of
54% (CI: 33%, 83%) and a responder rate of 61% (CI: 41%, 78%) one
year after receiving VNS.
4. Discussion
VNS therapy has been used since the 1990s as a treatment for
pharmacoresistant partial onset epilepsy.4,5 Elliott et al. reported a
61.0% mean seizure reduction in 18 patients with either a tumor,
cavernoma, or arteriovenous malformation; however, there is a
lack of studies exclusively on the subgroup of VNS therapy patients
with a brain tumor.26 As can be derived from the number of
patients with a history of brain tumor enrolled in the Cyberonics
registry, VNS therapy has been implemented in a limited fashion
by clinicians, indicating an implicit assumption on their part of
efﬁcacy in this particular subgroup. Nevertheless, there is likely a
large group of patients with epilepsy secondary to brain tumors
that is not offered VNS. Reasons for limited use may be the lack of
published evidence of efﬁcacy in this subgroup, lack of knowledge
of VNS therapy in neuro-oncologists who often treat patients with
brain tumor associated epilepsy, suspicion that tumor progression
will undermine therapeutic efﬁcacy, or belief that a potentially
limited life-expectancy may reduce the indication for another
surgical procedure, albeit a safe outpatient one.
A median seizure reduction of close to 50% indicates clear
efﬁcacy, similar to the efﬁcacy in non-tumor related epilepsy forVNS therapy in brain tumor-associated epilepsy. One characteristic
of long term VNS therapy is an increase in seizure control over
time.9 Our study shows a similar long term increase in median
seizure reduction and clinical responder rate in brain tumor
patients. The seizure response outcomes in the sub-analysis of
brain tumor patients who reported a prior resection surgery were
statistically equivalent to those patients without a report of prior
resection surgery.
Although VNS may be effective in this subpopulation, it is
critical to appreciate that the best treatment for brain tumor
associated epilepsy is complete resection of the mass lesion.
Gross total lesionectomy has been shown to have seizure-
freedom rates as high as 79%.27,28 In certain circumstances, an
additional ‘‘epilepsy’’ surgery with either implanted subdural
electrodes or resection of additional epileptogenic tissue is often
warranted and can lead to increases in rates of seizure-
freedom.27,29 Nevertheless, there is a signiﬁcant proportion of
patients in whom a portion of the tumor is unresectable or
adjacent tissue has been rendered epileptogenic. Some patients
may elect a lower risk procedure. In addition, there are patients
with prolonged remission of their tumor who still have
intractable epilepsy. If patients are not amenable to further
open surgery, and adequate trials of AEDs have been imple-
mented with seizure persistence, VNS therapy should be offered
as a potential therapeutic option.
Another important caveat is the histology of the tumor. The
most common cause of increased seizure frequency and intracta-
bility in patients with tumors is tumor progression. Patients with
anaplastic or malignant tumors, in whom tumor progression may
be imminent, are not likely to respond as effectively to VNS,
although our study did not analyze this variable, as tumor
progression data was not available in the registry. Seizure
reduction through adjuvant oncologic therapy such as chemother-
apy, immunotherapy, and radiation therapy may lead to more
effective seizure reduction through tumor control. Likewise,
patients with limited life expectancy may not want to undergo
further surgery, although VNS implantation is an outpatient, low
morbidity procedure.30 Though frequent MRI scans required to
follow patients with tumors may seem to be a barrier to VNS
implantation, certain MRI scans are conditionally safe as long as
particular precautions are made, including turning the device ‘‘off’’
before the scan and then turning it back ‘‘on’’ after the scan.31,32 In
addition, the position of the generator with respect to the MRI
scanner may reduce the need to turn the device ‘‘off’’.33
There are several limitations to this study. The ﬁrst is that
a registry is voluntary. The sample is not all patients with a
stimulator but rather patients whom treating physicians have
entered into the registry; therefore, there is the potential for
sample bias. Secondly, only patients with a medical history of brain
tumor and an etiology reportedly related to the tumor were
included, but the authors are unable to verify the clinical context in
which VNS was performed for these brain tumor patients. The third
limitation is that the histology of the tumor, progression of the
tumor, use of repeat tumor resection and additional adjuvant
therapy is not speciﬁed. Therefore, benign and malignant tumors of
all histologies are represented in this database without discrimi-
nation. Lack of efﬁcacy from tumor progression in more malignant
histologies would not be indicated, nor would false efﬁcacy from
additional tumor resection or adjuvant therapy that might lead to
increased seizure control. Overall, it is likely that more benign
histologies will lead to greater response rates since tumors will
progress more slowly, if at all. However, the most benign
pathologies, such as ganglioglioma or dysembryoplastic neuroe-
pithelial tumor (DNET) are often cured with lesionectomy alone
and do not likely represent a high proportion of intractable cases in
this database.34
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efﬁcacy of VNS therapy. Decreasing AED use can increase quality of
life by eliminating or reducing side effects. Reductions in AEDs can
lead to decreased interactions with chemotherapy drugs, as AED
interactions can reduce the efﬁcacy of anticancer drugs by
lowering drug concentrations via induction of the cytochrome
p450 system.35 This study shows a slight decrease in AEDs in both
brain tumor and non-brain tumor patients with VNS therapy. Of
the 19 brain tumor patients followed at least two years, 3 were
using at least one fewer AED at the end of the study (2 completely
off AEDs), 14 were using the same number of AEDs, and the
remaining 2 added at least one AED. Prior studies of AED
reductions from VNS therapy in non-brain tumor patients have
reported varied changes in AED use over time.36,37 For example,
Uthman et al. reported an increase in mean number of AEDs over
extended time on VNS while Tatum et al. found a signiﬁcant
decrease in AEDs in 42.9% of patients.38 These results suggest that
when discussing VNS with patients who have seizures and brain
tumors, perhaps physicians should be less conﬁdent in predicting
decreased AED burdens, and more conﬁdent in predicting seizure
rate reductions.
5. Conclusions
Our study supports the idea that VNS therapy is equally
effective in patients who suffer seizures secondary to brain tumors
as in patients without history of a brain tumor. VNS therapy should
be a viable treatment option for patients with brain tumor
associated medically intractable epilepsy, assuming cytoreductive
and other adjuvant therapies have been adequately explored.
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